1) GP Ⅱb/Ⅲa receptor antagonist
血小板膜糖蛋白受体拮抗剂
1.
Many clinical studies have confirmed that antiplatelet drugs act important roles to prevent and treat the cardiac disease,cerebrovascular disease and peripherial artery disease,such as aspirin,thienopyridine,GP Ⅱb/Ⅲa receptor antagonist,cilostazol and so on.
大量临床研究已证实抗血小板药物:阿司匹林、噻吩吡啶类药物、血小板膜糖蛋白受体拮抗剂、西洛他唑等在预防和治疗心脑血管疾病以及外周动脉血管病变中具有十分重要的作用。
2) Platelet glycoprotein Ⅱb/Ⅲa receptor inhibitor
血小板膜糖蛋白Ⅱb/Ⅲa受体拮抗剂
3) platelet glycoprotein IIb/IIIa receptor inhibitor
血小板膜糖蛋白IIb/IIIa受体拮抗剂
4) platelet membrane glycoprotein GPⅡb/Ⅲa receptor antagonists
血小板膜糖蛋白GPⅡb/Ⅲa受体拮抗剂
1.
RESULTS & CONCLUTION: As an wonderful antiplatelet drug,platelet membrane glycoprotein GPⅡb/Ⅲa receptor antagonists experienced a fast development,which showed a high selectivity to platelet membrane glycoprotein GPⅡb/Ⅲa receptor antagonists and exhibited a satisfactory prospect in the treatment of thrombus,acute myocardial infarction,acute c.
目的:本文介绍血小板膜糖蛋白GPⅡb/Ⅲa受体拮抗剂的进展与评价。
5) Patelet glycoprotein Ⅱb/Ⅲa receptor
血小板糖蛋白ⅡbⅢ/a受体拮抗剂
6) platelet glycoprotein Ⅱ b/Ⅲ a receptor inhibitor
血小板糖蛋白Ⅱb/Ⅲa受体拮抗剂
1.
In patients with acute coronary syndrome(ACS)or undergoing percutaneous coronary intervention(PCI),pharmacological blockade of the platelet glycoprotein Ⅱ b/Ⅲ a receptor inhibitor has emerged as a key strategy for improving clinical outcome.
急性冠状动脉综合征(ACS)或行经皮冠状动脉介入(PCI)的患者采用血小板糖蛋白Ⅱb/Ⅲa受体拮抗剂治疗对改善临床预后起着关键作用。
补充资料：牛乳清糖蛋白
CAS: 84082-51-9
中文名称: 牛乳清糖蛋白
英文名称: Glycoproteins, bovine-whey；Glycoproteins,bovine-whey
中文名称: 牛乳清糖蛋白
英文名称: Glycoproteins, bovine-whey；Glycoproteins,bovine-whey
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条